# US 2014/0271681 A1 · High Affinity Human Antibodies to Human IL-4 Receptor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0271681 A1
- Document ID: US20140271681A1
- Status: Published application
- Kind: A1
- Application number: 14/254,369
- Filed: 2014-04-16
- Published: 2014-09-18
- Earliest claimed: 2006-10-02
- Assignees: Regeneron Pharmaceuticals, Inc.
- Applicants: Regeneron Pharmaceuticals, Inc.
- Inventors: Joel H. Martin; Tammy T. Huang; Jeanette L. Fairhurst; Nicholas J. Papadopoulos
- Web page: https://patentgrep.com/patent/US20140271681A1

## CPC

- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/06: Antianaemics
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 13/08: of the prostate
- A61P 13/12: of the kidneys
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/04: Antipruritics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 31/06: for tuberculosis
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides nucleic acid molecules that encode antibodies or antigen-binding fragments thereof, which specifically bind human interleukin-4 receptor (IL-4R). Also provided are expression vectors comprising nucleic acid molecule that encode anti-IL-4R antibodies, host cells comprising the expression vectors, and methods of producing anti-IL-4R antibodies or antigen-binding fragments thereof comprising growing the host cells under conditions permitting production of the antibody or fragment, and recovering the antibody or fragment so produced

## Claims

### Claim at position 1

1-29. (canceled)

### Claim 30

An antibody or antigen-binding fragment of an antibody which specifically binds human IL-4R, comprising heavy chain complementarity determining region 1 (HCDR1), 2 (HCDR2), 3 (HCDR3) and light chain complementarity determining region 1 (LCDR1), 2 (LCDR2), 3 (LCDR3), wherein
HCDR1 comprises an amino acid sequence of the formula X1-X2-X3-X4-X5-X6-X7-X8 (SEQ ID NO:265), wherein X1=Gly; X2=Phe; X3=Thr; X4=Phe; X5=Asp or Arg; X6=Asp or Ser; X7=Tyr; and X8=Ala or Gly;
HCDR2 comprises an amino acid sequence of the formula X1-X2-X3-X4-X5-X6-X7-X8 (SEQ ID NO:266), wherein X1=Ile or Leu, X2=Ser, X3=Gly, Tyr or Arg, X4=Ser, Asp or Thr, X5=Gly or Ser, X6=Gly, Ser or Val, X7=Ser or Asn, and X8=Thr, Lys or Ile;
HCDR3 comprises an amino acid sequence of the formula X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15-X16-X17-X18 (SEQ ID NO:267) wherein X1=Ala, X2=Lys, X3=Asp, Glu or Trp, X4=Gly or Arg, X5=Leu, Thr or Arg, X6=Gly, Arg or Ser, X7=Ile or Gly, X8=Thr, Phe or Tyr, X9=Ile, Asp or Phe, X10=Arg, Tyr or Asp, X11=Pro, Tyr or absent, X12=Arg or absent, X13=Tyr or absent, X14=Tyr or absent, X15=Gly or absent, X16=Leu or absent, X17=Asp or absent, and X18=Val or absent;
LCDR1 comprises an amino acid sequence of the formula X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11 (SEQ ID NO:268) wherein X=Gln, X2=Asp, Ser or Val, X3=Ile or Leu, X4=Ser, Leu or Asn, X5=Asn, Tyr or Ile, X6=Trp, Ser or Tyr; X7=ile or absent; X8=Gly or absent; X9=Tyr or absent; X10=Asn or absent; and X11=Tyr or absent;
LCDR2 comprises an amino acid sequence of the formula X1-X2-X3 (SEQ ID NO:269) wherein X1=Leu, Ala or Val, X2=Ala or Gly, and X3=Ser; and
LCDR3 comprises an amino acid sequence of the formula X1-X2-X3-X4-X5-X6-X7-X8-X9 (SEQ ID NO. 270) wherein X1=Gln or Met, X2=Gln, X3=Ala or Tyr, X4=Leu or Asn, X5=Gn or Ser, X6=Thr, Phe or His, X7=Pro, X8=Tyr, Ile or Trp, and X9=Thr.

### Claim 31 (depends on 30)

The antibody or antigen-binding fragment of claim 30, wherein the heavy and light chain CDR amino acid sequences (HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3) have the amino acid sequences of SEQ ID NO: 148, 150, 152, 156, 158, and 160, respectively.

### Claim 32 (depends on 30)

The antibody or antigen-binding fragment of claim 30, wherein the heavy and light chain CDR amino acid sequences (HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3) are encoded by nucleotide sequences of SEQ ID NO:147, 149, 151, 155, 157, and 159, respectively.

### Claim 33 (depends on 30)

The antibody or antigen-binding fragment according to claim 30, wherein the antibody or antigen binding fragment comprises a heavy chain variable region (HCVR) having an amino acid sequence of SEQ ID NO: 162 and a light chain variable region (LCVR) having an amino acid sequence of SEQ ID NO: 164.

### Claim 34 (depends on 30)

The antibody or antigen-binding fragment according to claim 30, characterized by an affinity for hIL-4R (KD) of ≦300 pM.

### Claim 35 (depends on 30)

The antibody or antigen-binding fragment according to claim 30, characterized by an affinity for hIL-4R (KD) of ≦100 pM.

### Claim 36 (depends on 30)

The antibody or antigen-binding fragment according to claim 30, characterized by an affinity for hIL-4R (KD) of ≦50 pM.

### Claim 37 (depends on 30)

The antibody or antigen-binding fragment according to claim 30, wherein the antibody or fragment thereof cross-reacts with monkey IL-4R.

### Claim 38 (depends on 30)

The antibody or antigen binding fragment according to claim 30 for use in the treatment of asthma or atopic dermatitis.

### Claim 39 (depends on 30)

A nucleic acid sequence encoding the antibody or antigen binding fragment of claim 30.

### Claim 40 (depends on 39)

A vector comprising the nucleic acid sequence of claim 39.

### Claim 41 (depends on 40)

An isolated host cell comprising the vector of claim 40.

### Claim 42 (depends on 30)

A therapeutic composition comprising the antibody or antigen-binding fragment according to claim 30 and an acceptable carrier.

### Claim 43 (depends on 42)

The therapeutic composition of claim 42, further comprising a second therapeutic agent selected from montelukast, pranlukast, zafirlust, and rilonacept.

### Claim 44 (depends on 30)

The antibody or antigen binding fragment according to claim 30 for use in the treatment of asthma.

### Claim 45 (depends on 30)

The antibody or antigen binding fragment according to claim 30 for use in the treatment of atopic dermatitis.

### Claim 46 (depends on 30)

The antibody or antigen binding fragment of claim 30, wherein the antibody or antigen-binding fragment thereof is a human antibody, and wherein the antibody or antigen-binding fragment thereof is made in a transgenic mouse.

### Claim 47 (depends on 30)

The antibody or antigen binding fragment of claim 30, wherein the antibody or antigen-binding fragment is a human antibody, and wherein the antibody or antigen-binding fragment thereof is isolated from a hybridoma that is derived from a B cell that is isolated from a transgenic mouse.

### Claim 48

A therapeutic composition comprising an antibody or antigen-binding fragment, and a pharmaceutically acceptable carrier, wherein the antibody or antigen binding fragment comprises a heavy chain variable region (HCVR) having an amino acid sequence of SEQ ID NO: 162 and a light chain variable region (LCVR) having an amino acid sequence of SEQ ID NO:164.

### Claim 49

A therapeutic composition comprising an antibody or antigen-binding fragment, and a pharmaceutically acceptable carrier, wherein the antibody or antigen binding fragment comprises heavy and light chain CDR amino acid sequences (HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3) having the amino acid sequences of SEQ ID NO:148, 150, 152, 156, 158, and 160, respectively.
